Sae Yumita

Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real‐world practice

Miyuki Nakagawa, Masanori Inoue, Sadahisa Ogasawara et al. · Cancer · 2022 · 27 citations

Medicine, Oncology, Pharmacology +15

Effect of Atezolizumab plus Bevacizumab in Patients with Hepatocellular Carcinoma Harboring <i>CTNNB1</i> Mutation in Early Clinical Experience

Keita Ogawa, Hiroaki Kanzaki, Tetsuhiro Chiba et al. · Journal of Cancer · 2022 · 19 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Miglustat, a glucosylceramide synthase inhibitor, mitigates liver fibrosis through TGF-β/Smad pathway suppression in hepatic stellate cells

T. Iwanaga, Tetsuhiro Chiba, Masato Nakamura et al. · Biochemical and Biophysical Research Communications · 2022 · 14 citations

Life Sciences, Biochemistry, Pathology +15

Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial

Sadahisa Ogasawara, Keisuke Koroki, Hirokazu Makishima et al. · BMJ Open · 2022 · 12 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice

Sae Yumita, Sadahisa Ogasawara, Miyuki Nakagawa et al. · BMC Gastroenterology · 2023 · 10 citations · Full text

Medicine, Oncology, Pharmacotherapy +17